Skip To Main Content
Andrew McConaghie on Muck Rack

Andrew McConaghie

Verified
Europe, United Kingdom
As seen in: Scrip, BioXconomy, Pharmaphorum, HBW Insight, PMLiVE, Citeline, Generics Bulletin, In Vivo, The Pink Sheet, In Vivo Podcasts
Senior Writer, Scrip. Pharma and healthcare updates

Get in touch with Andrew

Contact Andrew, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Novo Looks To Direct-To-Consumer And Diversification To Lift Growth

|
By Andrew McConaghie Verified
| Scrip Verified
The company wants to to build on the Wegovy pill success but forecast of sector-average growth sees share price decline again Novo has unveiled a renewed business strategy for up to 2030, aiming to persuade skeptical investors that it can sustain growth despite pipeline setbacks and a looming patent expiry on its mega-blockbuster GLP-1 agonist, semaglutide (Wegovy/Ozempic) . The firm kicked off its Capital Markets Day in London on Sept. 21 with pledges from CEO Mike Doustdar to...
Open in Who Shared Issue with article?

Long Wait Is Good Omen For AstraZeneca’s AVANZAR Lung Cancer Trial

|
By Andrew McConaghie Verified
| Scrip Verified
Analysts have been reading the runes on the outcome of AstraZeneca’s key lung cancer study AVANZAR, and some have concluded the extended wait for a result is a good omen. AVANZAR is one of the firm’s biggest oncology bets in years, and looks to make TROP2-directed antibody-drug conjugate (ADC) Datroway...
Open in Who Shared Issue with article?

China May Follow US To Limit Biotech Deals, Pfizer CEO Warns

|
By Andrew McConaghie Verified
| The Pink Sheet Verified
Big pharma execs are opposed to US lawmakers restricting cross-border biotech deals, but now must argue against similar moves from China. Key Takeaways China has changed its regulations to create restrictions similar to the pending US legislation that aims to make biopharma deals subject to “outbound investment screening.” Big pharma has concerns about US lawmakers potentially restricting its dealmaking activities with Chinese biotechs, but could soon be grappling...
Open in Who Shared Issue with article?
See all 2,334 articles